PRODUCT INFORMATION

Cevipabulin

Item No. 33224

CAS Registry No.: 849550-05-6
Formal Name: 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy] phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4] triazolo[1,5-a]pyrimidin-7-amine
Synonym: TTI-237
MF: $C_{18}H_{18}ClF_5N_6O$
FW: 464.8
Purity: ≥98%
UV/Vis.: λ_{max}: 224, 297 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cevipabulin is supplied as a crystalline solid. A stock solution may be made by dissolving the cevipabulin in the solvent of choice, which should be purged with an inert gas. Cevipabulin is soluble in the organic solvent DMSO.

Description

Cevipabulin is an activator of microtubule polymerization.[1,2] It induces aggregation of isolated bovine brain tubulin in a concentration-dependent manner.[1] Cevipabulin (100 µM) inhibits binding of vinblastine (Item No. 11762), but not colchicine (Item No. 9000760), to tubulin in cell-free assays. It induces mitotic block in HeLa cells when used at a concentration of 68 nM and is cytotoxic to MDA-MB-468, MDA-MB-435, LNCaP, SKOV3, and HeLa cancer cell lines (IC_{50}s = 18-40 nM). Cevipabulin (20 mg/kg, i.v.) reduces tumor growth in a LoVo colon adenocarcinoma mouse xenograft model.

References

1. Beyer, C.F., Zhang, N., Hernandez, R., *et al.* TTI-237: A novel microtubule-active compound with *in vivo* antitumor activity. *Cancer Res.* **68(7)**, 2292-2300 (2008).
2. Beyer, C.F., Zhang, N., Hernandez, R., *et al.* The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties. *Cancer Chemother. Pharmacol.* **64(4)**, 681-689 (2009).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM